Keytruda (pembrolizumab) has been approved in China for first-line treatment of certain patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1.
The approval makes the Merck & Co (NYSE: MRK) drug the first anti-PD-1 therapy to be approved as monotherapy and in combination with chemotherapy in the first-line setting for NSCLC in China.
This new indication was granted full approval based on the overall survival findings from the Phase III KEYNOTE-042 trial, including data from an extension of the global study in Chinese patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze